EBSHealthcare · Drug Manufacturers - Specialty & GenericThe 3 Wall Street analysts covering Emergent BioSolutions, Inc. hold a median 12-month price target of $11 — +55.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 27 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Emergent BioSolutions, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Volatility (16): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on EBS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +55.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 21 Aug 2026 | JP Morgan | Reinstates | Underweight | — |
| 10 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $12 → $10 |
| 10 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | $15 → $12 |
| 16 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Dec 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 7 Nov 2024 | Benchmark | Maintains | Buy | — |
| 13 Sept 2024 | Rodman & Renshaw | Reiterates | Buy | — |
| 22 Aug 2024 | Rodman & Renshaw | Initiates | Buy | — |
| 16 Aug 2024 | Benchmark | Reiterates | Buy | — |
| 9 Aug 2024 | Benchmark | Reiterates | Buy | — |
| 3 July 2024 | Benchmark | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
EBS appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Emergent BioSolutions, Inc. returned −25.1% against +13.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 61% of US stocks
Cheaper than 84% of US stocks
Cheaper than 72% of US stocks
Cheaper than 56% of US stocks
Higher than 89% of US stocks
Higher than 80% of US stocks
Higher than 70% of US stocks
Higher than 86% of US stocks
Higher than 15% of US stocks
Higher than 24% of US stocks
Higher than 85% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Emergent BioSolutions, Inc. has a market value of $342.0M and an enterprise value of $790.5M.
Revenue in the twelve months to 30 June 2026: $742.3M. The latest quarter grew 66.3% year on year.
Net income over the same four quarters: −$176.8M, a −23.8% net margin.
Diluted earnings per share, trailing twelve months: $−3.55.
Free cash flow in the twelve months to 30 June 2026: $85.9M.
Emergent BioSolutions, Inc. spent $36.0M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 8.6×; forward P/E: 6.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Emergent BioSolutions, Inc. employs 900 people — $825K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Emergent BioSolutions, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Emergent BioSolutions announced that CFO Richard S. Lindahl will retire effective December 31, 2026. Treasurer Frank Vargo will become interim CFO on January 1, 2027, while Lindahl serves as a senior executive advisor through March 31, 2027.
Why it matters — The announcement outlines the timing and transition arrangements for a change in EBS’s finance leadership.
Emergent BioSolutions will host a conference call on November 2, 2026, at 5:00 p.m. Eastern to discuss its third-quarter 2026 financial results. The call will be available by webcast and teleconference, with pre-registration offered.
Why it matters — EBS watchers can use the call to hear the company discuss its third-quarter financial results.
Emergent BioSolutions (EBS) rose 14.4% on higher-than-average trading volume in its last session. However, the latest trend in earnings estimate revisions may not support further near-term upside for the stock.
Why it matters — EBS watchers would care because the stock's recent price surge may not be backed by improving earnings estimates, suggesting limited near-term momentum.
A researcher at a Siberian anti-plague facility in the Irkutsk region was fatally exposed to Yersinia pestis, causing pneumonic plague, prompting Russian officials to quarantine several regional hospitals and isolate nearly 200 contacts.
Why it matters — Emergent BioSolutions develops medical countermeasures against biological threats, so a plague outbreak could draw attention to its biodefense and public-health products.
Emergent BioSolutions announced it will host a ribbon cutting ceremony on September 16 at its Canton, Massachusetts facility to celebrate the restart and growth of manufacturing at the site and the company's investment in advanced biopharmaceutical manufacturing in the Commonwealth.
Why it matters — EBS watchers would care because the restart and expansion of the Canton manufacturing facility signals renewed operational capacity and long-term investment in Emergent's production footprint.
The 3 Wall Street analysts covering Emergent BioSolutions, Inc. have a median 12-month price target of $11, with estimates ranging from $10 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Emergent BioSolutions, Inc., 2 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Emergent BioSolutions, Inc. 92 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Emergent BioSolutions, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +55.1% from the last close, and Ticker Nerd's factor model ranks Emergent BioSolutions, Inc. 92 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Emergent BioSolutions, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EBS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $12 over the next 12 months.
Emergent BioSolutions, Inc. returned -25.1% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Emergent BioSolutions Inc. is a life sciences company focused on preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats.
The most recent item we track (Business Wire, 16 Oct 2026): "Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl". Emergent BioSolutions announced that CFO Richard S. Lindahl will retire effective December 31, 2026. Treasurer Frank Vargo will become interim CFO on January 1, 2027, while Lindahl serves as a senior executive advisor through March 31, 2027.
Emergent BioSolutions Inc. is a life sciences company focused on preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats. Its current business centers on medical countermeasures and specialty products, including public health protection tools used by government agencies, healthcare providers, and other institutional customers. The company’s portfolio includes commercial products, medical countermeasure products, and services, with an emphasis on areas such as opioid overdose reversal, smallpox and anthrax preparedness, and contract development and manufacturing support. Emergent BioSolutions plays a specialized role in the healthcare and biodefense markets by supplying products and services designed to support emergency readiness and public health response across the United States and international markets.
CEO Mr. Joseph C. Papa Jr., M.B.A., R.Ph. · 900 employees · United States · https://www.emergentbiosolutions.com
